RU2015141428A - Антитела, связывающие il-4 и/или il-13, и их применение - Google Patents
Антитела, связывающие il-4 и/или il-13, и их применение Download PDFInfo
- Publication number
- RU2015141428A RU2015141428A RU2015141428A RU2015141428A RU2015141428A RU 2015141428 A RU2015141428 A RU 2015141428A RU 2015141428 A RU2015141428 A RU 2015141428A RU 2015141428 A RU2015141428 A RU 2015141428A RU 2015141428 A RU2015141428 A RU 2015141428A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- fragment
- amino acid
- variable domain
- acid sequence
- Prior art date
Links
- 108090000978 Interleukin-4 Proteins 0.000 title claims 2
- 239000012634 fragment Substances 0.000 claims 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- -1 radionuclide Proteins 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (29)
1. Выделенное антитело или его фрагмент, которые специфически связываются с IL-13, где антитело или его фрагмент содержат:
(a) вариабельный домен легкой цепи, содержащий аминокислотную последовательность SEQ ID NO: 1, и вариабельный домен тяжелой цепи, содержащий аминокислотную последовательность SEQ ID NO: 2; или
(b) вариабельный домен легкой цепи, содержащий аминокислотные последовательности RASESVDSYGQSYMH (CDR1), LASNLES (CDR2) и QQNAEDSRT (CDR3), и вариабельный домен тяжелой цепи, содержащий аминокислотные последовательности GFSLTDSSIN (CDR1), DGRID (CDR2) и DGYFPYAMDF (CDR3).
2. Выделенное антитело или его фрагмент, которые специфически связываются с IL-13, где антитело или его фрагмент содержат вариабельный домен легкой цепи, содержащий аминокислотную последовательность, которая по меньшей мере на 95% идентична аминокислотной последовательности SEQ ID NO: 1, и вариабельный домен тяжелой цепи содержащий аминокислотную последовательность, которая по меньшей мере на 95% идентична аминокислотной последовательности SEQ ID NO: 2.
3. Выделенное антитело или его фрагмент, которые специфически связываются с тем же эпитопом на IL-13, с которым связываются антитело или его фрагмент, содержащие:
(а) вариабельный домен легкой цепи, содержащий аминокислотную последовательность SEQ ID NO: 1, и вариабельный домен тяжелой цепи, содержащий аминокислотную последовательность SEQ ID NO: 2; или
(b) вариабельный домен легкой цепи, содержащий аминокислотные последовательности RASESVDSYGQSYMH (CDR1), LASNLES (CDR2) и QQNAEDSRT (CDR3), и вариабельный домен тяжелой цепи, содержащий аминокислотные последовательности GFSLTDSSIN (CDR1), DGRID (CDR2) и DGYFPYAMDF (CDR3).
4. Выделенное антитело или его фрагмент, которые специфически связываются с IL-13, где антитело или его фрагмент конкурентно ингибируют связывание антитела или его фрагмента, содержащих:
(a) вариабельный домен легкой цепи, содержащий аминокислотную последовательность SEQ ID NO: 1, и вариабельный домен тяжелой цепи, содержащий аминокислотную последовательность SEQ ID NO: 2; или
(b) вариабельный домен легкой цепи, содержащий аминокислотные последовательности RASESVDSYGQSYMH (CDR1), LASNLES (CDR2) и QQNAEDSRT (CDR3), и вариабельный домен тяжелой цепи, содержащий аминокислотные последовательности GFSLTDSSIN (CDR1), DGRID (CDR2) и DGYFPYAMDF (CDR3).
5. Антитело или фрагмент антитела по п. 1, где антитело представляет собой биспецифическое антитело или фрагмент этого биспецифического антитела.
6. Антитело или фрагмент антитела по п. 5, где антитело специфически связывается с IL-13 и IL-4.
7. Антитело или его фрагмент по п. 1, где антитело или его фрагмент содержат константные домены.
8. Антитело или его фрагмент по п. 7, где константные домены выбраны из группы, состоящей из CH1, СН2 СН3 и CL.
9. Антитело или его фрагмент по п. 1, где антитело или его фрагмент представляют собой антитело IgG или его фрагмент.
10. Антитело или его фрагмент по п. 9, где антитело IgG или его фрагмент представляют собой антитело IgG4 или его фрагмент.
11. Антитело или его фрагмент по п. 1, которые дополнительно конъюгированы с эффекторной молекулой.
12. Антитело или его фрагмент по п. 11, где эффекторная молекула представляет собой гетерологичный полипептид, лекарственное средство, радионуклид или токсин.
13. Фармацевтическая композиция, содержащая антитело или его фрагмент по любому из пп. 1-12 и фармацевтически приемлемый носитель.
14. Антитело или его фрагмент по любому из пп. 1-10, которые дополнительно содержат метку, где метка является радиоизотопной меткой, флуорофором, хромофором, контрастным агентом или ионом металла.
15. Применение терапевтически эффективного количества антитела или его фрагмента по любому из пп. 1-10, где антитело или его фрагмент служат для получения лекарственного средства для лечения заболевания, опосредованного IL-13.
16. Применение по п. 15, где заболевание, опосредованное IL-13, представляет собой аллергическое заболевание, рак, астму, заболевание, связанное с патологической продукцией IL-13, аутоиммунное заболевание, склеродерму или идиопатический легочный фиброз.
17. Антитело или его фрагмент по любому из пп. 1-10 для получения лекарственного средства для лечения, подавления или профилактики заболевания, опосредованного IL-13, у млекопитающего.
18. Антитело или его фрагмент по п. 17, где заболевание, опосредованное IL-13, выбрано из группы, состоящей из аллергического заболевания, астмы, рака, аутоиммунного заболевания, заболевания, связанного с патологической продукцией IL-13, склеродермы и идиопатического легочного фиброза.
19. Применение терапевтически эффективного количества антитела или его фрагмента по любому из пп. 1-10, где антитело или его фрагмент служат для получения лекарственного средства, которое используется для подавления ответа, опосредованного ΊΉ-2.
20. Антитело или фрагмент по любому из пп. 1-10 для применения для подавления ответа, опосредованного ТН2, у млекопитающего.
21. Выделенная молекула нуклеиновая кислота, кодирующая антитело или его фрагмент по любому из пп. 1-10.
22. Вектор, содержащий молекулу нуклеиновой кислоты по п. 21.
23. Выделенная клетка-хозяин, содержащая вектор по п. 22.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291259.5 | 2007-10-15 | ||
| EP07291259A EP2050764A1 (en) | 2007-10-15 | 2007-10-15 | Novel polyvalent bispecific antibody format and uses thereof |
| US3712808P | 2008-03-17 | 2008-03-17 | |
| US61/037,128 | 2008-03-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013120318/10A Division RU2580049C2 (ru) | 2007-10-15 | 2008-10-14 | Антитела, связывающие il-4 и/или il-13, и их применение |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2015141428A true RU2015141428A (ru) | 2017-04-04 |
| RU2015141428A3 RU2015141428A3 (ru) | 2019-04-30 |
| RU2705551C2 RU2705551C2 (ru) | 2019-11-07 |
Family
ID=39313041
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013120318/10A RU2580049C2 (ru) | 2007-10-15 | 2008-10-14 | Антитела, связывающие il-4 и/или il-13, и их применение |
| RU2010119521/10A RU2488595C2 (ru) | 2007-10-15 | 2008-10-14 | Антитела, связывающие il-4 и/или il-13, и их применение |
| RU2015141428A RU2705551C2 (ru) | 2007-10-15 | 2015-09-29 | Антитела, связывающие il-4 и/или il-13, и их применение |
| RU2015141418A RU2721236C2 (ru) | 2007-10-15 | 2015-09-29 | Антитела, связывающие il-4 и/или il-13, и их применение |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013120318/10A RU2580049C2 (ru) | 2007-10-15 | 2008-10-14 | Антитела, связывающие il-4 и/или il-13, и их применение |
| RU2010119521/10A RU2488595C2 (ru) | 2007-10-15 | 2008-10-14 | Антитела, связывающие il-4 и/или il-13, и их применение |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015141418A RU2721236C2 (ru) | 2007-10-15 | 2015-09-29 | Антитела, связывающие il-4 и/или il-13, и их применение |
Country Status (43)
Families Citing this family (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US20090148905A1 (en) * | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| AU2009282234A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| EP2334705B1 (en) | 2008-09-26 | 2016-12-14 | UCB Biopharma SPRL | Biological products |
| EP2414391B1 (en) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US20120283415A1 (en) * | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
| NZ701769A (en) | 2009-09-16 | 2016-06-24 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
| GB201000467D0 (en) * | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
| EP2596114A4 (en) * | 2010-07-14 | 2014-01-08 | Amgen Inc | IMMUNOGLOBULIN WITH DOMAIN INSERTION |
| EP3960865A1 (en) | 2010-08-02 | 2022-03-02 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
| WO2012018790A2 (en) | 2010-08-03 | 2012-02-09 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| MX341921B (es) | 2011-02-28 | 2016-09-07 | Hoffmann La Roche | Proteinas de union a antigeno. |
| CN102675460B (zh) * | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
| TWI719112B (zh) * | 2011-03-16 | 2021-02-21 | 賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| TWI803876B (zh) * | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| ES2859906T3 (es) * | 2011-03-28 | 2021-10-04 | Sanofi Sa | Proteínas de unión similares a anticuerpos con regiones variables duales con una orientación de entrecruzamiento de la región de unión |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| HUE047278T2 (hu) | 2011-08-05 | 2020-04-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| CN108864261A (zh) | 2011-11-23 | 2018-11-23 | 拜奥文斯瑞有限公司 | 重组蛋白及其治疗用途 |
| WO2013103783A1 (en) * | 2012-01-04 | 2013-07-11 | Sanofi Us | Murine il-13 antibodies |
| RU2644341C2 (ru) | 2012-02-10 | 2018-02-08 | Дженентек, Инк. | Одноцепочечные антитела и другие гетеромультимеры |
| SG11201405830VA (en) * | 2012-03-27 | 2014-10-30 | Genentech Inc | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
| US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| CA2871882A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| KR20150023889A (ko) | 2012-06-27 | 2015-03-05 | 에프. 호프만-라 로슈 아게 | 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도 |
| MX371344B (es) | 2012-08-21 | 2020-01-27 | Regeneron Pharma | Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa. |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| ES2684549T3 (es) | 2012-09-12 | 2018-10-03 | Genzyme Corporation | Polipéptidos que contienen Fc con glicosilación alterada y función efectora reducida |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| CN105431453A (zh) | 2012-11-01 | 2016-03-23 | 艾伯维公司 | 稳定的双重可变结构域免疫球蛋白制剂 |
| AR093311A1 (es) | 2012-11-01 | 2015-05-27 | Abbvie Inc | Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4) |
| KR102408660B1 (ko) | 2012-11-20 | 2022-06-15 | 사노피 | 항-ceacam5 항체 및 이의 용도 |
| JP6441232B2 (ja) | 2012-12-27 | 2018-12-19 | サノフイＳａｎｏｆｉ | 抗ｌａｍｐ１抗体および抗体薬物コンジュゲート、ならびにその使用 |
| CN111875705B (zh) | 2013-03-11 | 2024-04-02 | 建新公司 | 高度糖基化的结合多肽 |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| CN105530959B (zh) * | 2013-03-15 | 2021-09-17 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| WO2014151910A1 (en) * | 2013-03-15 | 2014-09-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| RU2015141529A (ru) * | 2013-04-05 | 2017-05-15 | Дженентек, Инк. | Антитела и биспецифические антитела к il-4 и их применение |
| TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| AU2014342103B2 (en) | 2013-10-31 | 2020-06-04 | Sanofi-Aventis U.S. Llc. | Specific anti-CD38 antibodies for treating human cancers |
| US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| MX2016006529A (es) * | 2013-12-20 | 2016-08-03 | Genentech Inc | Anticuerpos dobles especificos. |
| EP2893939A1 (en) | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
| US20150225479A1 (en) * | 2014-02-12 | 2015-08-13 | Sanofi | Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations |
| MX2016010729A (es) * | 2014-02-21 | 2016-10-26 | Genentech Inc | Anticuerpos biespecificos anti-il-13 / il-17 y sus usos. |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by adding an IL-4R antagonist |
| CN106471010A (zh) | 2014-03-19 | 2017-03-01 | 建新公司 | 靶向模块的位点特异性糖工程化 |
| KR20160131118A (ko) | 2014-03-21 | 2016-11-15 | 리제너론 파마슈티칼스 인코포레이티드 | 상이한 결합 특징을 전시하는 vl 항원 결합 단백질 |
| CN106255410B (zh) | 2014-03-21 | 2020-01-10 | 瑞泽恩制药公司 | 产生单结构域结合蛋白的非人动物 |
| TWI745962B (zh) | 2014-06-27 | 2021-11-11 | 法商賽諾菲公司 | 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法 |
| NZ766128A (en) | 2014-07-11 | 2024-07-05 | Genmab As | Antibodies binding axl |
| WO2016044707A1 (en) * | 2014-09-18 | 2016-03-24 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
| CA3205824A1 (en) | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| JP6861630B2 (ja) | 2014-11-14 | 2021-04-21 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法 |
| WO2016080510A1 (ja) * | 2014-11-21 | 2016-05-26 | アステラス製薬株式会社 | 新規二重特異的抗体フォーマット |
| PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| EP4039710A3 (en) | 2015-01-23 | 2022-10-19 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| JP2018511797A (ja) * | 2015-03-16 | 2018-04-26 | ジェネンテック， インコーポレイテッド | ＩＬ−１３の検出方法及び定量方法並びにＴｈ２関連疾患の診断及び治療における使用 |
| CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EA201890272A1 (ru) | 2015-07-10 | 2018-08-31 | Генмаб А/С | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака |
| PL3365366T3 (pl) | 2015-10-25 | 2022-01-31 | Sanofi | Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV |
| AR106543A1 (es) | 2015-11-02 | 2018-01-24 | Netris Pharma | Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético |
| WO2017117384A1 (en) | 2015-12-31 | 2017-07-06 | Development Center For Biotechnology | Anti-vegfr antibody and uses thereof |
| KR20180117102A (ko) | 2016-01-08 | 2018-10-26 | 바이오얼라이언스 씨.브이. | 사가 항-psgl-1 항체 및 이들의 용도 |
| US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| CR20180539A (es) | 2016-04-13 | 2019-02-15 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes |
| EP4257193A3 (en) | 2016-04-13 | 2024-01-24 | Sanofi | Trispecific and/or trivalent binding proteins |
| ES2981704T3 (es) | 2016-04-27 | 2024-10-10 | Abbvie Mfg Management Unlimited Company | Métodos de tratamiento de enfermedades en las que la actividad de IL-13 es perjudicial mediante la utilización de anticuerpos anti-IL-13 |
| TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案 |
| SG11201811431VA (en) | 2016-07-14 | 2019-01-30 | Genmab As | Multispecific antibodies against cd40 and cd137 |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| CA3034768A1 (en) | 2016-08-26 | 2018-03-01 | Sanofi | Multispecific antibodies facilitating selective light chain pairing |
| US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
| KR20190070977A (ko) | 2016-11-01 | 2019-06-21 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
| US20180164221A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| KR102679324B1 (ko) | 2017-01-05 | 2024-06-28 | 네트리 파르마 | 네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료 |
| US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| KR20240049621A (ko) | 2017-02-17 | 2024-04-16 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
| KR101961871B1 (ko) * | 2017-02-20 | 2019-07-17 | 주식회사 와이바이오로직스 | 신규 다중특이적 결합 단백질 |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| EP3635005A1 (en) | 2017-06-07 | 2020-04-15 | Genmab B.V. | Therapeutic antibodies based on mutated igg hexamers |
| JP2020525470A (ja) * | 2017-07-03 | 2020-08-27 | ディヴェロップメント センター フォー バイオテクノロジー | 抗ｖｅｇｆｒ抗体及びその使用 |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| WO2019051204A1 (en) | 2017-09-08 | 2019-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER |
| US11186649B2 (en) | 2017-10-10 | 2021-11-30 | Sanofi | Anti-CD38 antibodies and methods of use |
| CN109705217B (zh) * | 2017-10-25 | 2020-09-11 | 北京智仁美博生物科技有限公司 | 抗il-13抗体及其用途 |
| PL3703818T3 (pl) | 2017-10-30 | 2024-03-25 | Sanofi Biotechnology | Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie |
| US11067584B2 (en) | 2018-01-12 | 2021-07-20 | Genzyme Corporation | Methods for the quantitation of polypeptides |
| MA51666A (fr) | 2018-01-24 | 2020-12-02 | Genmab Bv | Variants polypeptidiques et leurs utilisations |
| MX2020007882A (es) | 2018-01-26 | 2020-12-03 | Genzyme Corp | Variantes fc con unión mejorada a fcrn y semivida prolongada. |
| JP7497292B2 (ja) * | 2018-03-05 | 2024-06-10 | エタブリスモン フランセ ドュ サン | 遺伝子組換え単鎖免疫グロブリン |
| WO2019173719A1 (en) * | 2018-03-09 | 2019-09-12 | The Brigham And Women's Hospital, Inc. | Combination therapy for cardiovascular diseases |
| CN112839958A (zh) | 2018-05-03 | 2021-05-25 | 根马布私人有限公司 | 抗体变体组合及其用途 |
| EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| JP7513530B2 (ja) | 2018-06-22 | 2024-07-09 | ジェンマブ ホールディング ビー．ブイ． | 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法 |
| PE20211858A1 (es) | 2018-07-13 | 2021-09-21 | Genmab As | Variantes de anticuerpos anti-cd38 y sus usos |
| US20240254252A1 (en) | 2018-07-13 | 2024-08-01 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
| BR112021006055A2 (pt) | 2018-10-04 | 2021-07-20 | Genmab Holding B.V. | composição farmacêutica, uso da composição farmacêutica, e, métodos para induzir a morte celular ou para inibir o crescimento e/ou proliferação de uma célula tumoral e para tratar um indivíduo. |
| AU2019357467A1 (en) | 2018-10-09 | 2021-05-27 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
| US20210403580A1 (en) * | 2018-11-09 | 2021-12-30 | Ajou University Industry-Academic Cooperation Foundation | Human antibody having high affinity to human il-4 receptor alpha, and use thereof |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| SG11202106295WA (en) | 2018-12-21 | 2021-07-29 | Aim Immunotech Inc | Compositions and methods for cancer therapy |
| CN111494626B (zh) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| AU2020231343A1 (en) | 2019-03-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer |
| CN113597328A (zh) | 2019-03-21 | 2021-11-02 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| US11827671B2 (en) | 2019-05-24 | 2023-11-28 | Sanofi | Methods for treating systemic sclerosis |
| EP3753954A1 (en) | 2019-06-21 | 2020-12-23 | Université de Franche-Comté | Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells |
| KR20220034857A (ko) | 2019-07-16 | 2022-03-18 | 사노피 | 알츠하이머병의 치료를 위한 중화 항-아밀로이드 베타 항체 |
| KR20220038432A (ko) | 2019-07-25 | 2022-03-28 | 젠자임 코포레이션 | FcRn 길항제를 이용한 항체-매개 장애의 치료 방법 |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP4090365A1 (en) | 2020-01-15 | 2022-11-23 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| US20230047809A1 (en) | 2020-01-31 | 2023-02-16 | Sanofi | Pulmonary delivery of antibodies |
| IL295590A (en) | 2020-02-28 | 2022-10-01 | Genzyme Corp | Optimized binding polypeptides to optimize drug conjugation |
| KR20220149579A (ko) | 2020-03-03 | 2022-11-08 | 액티브 바이오테크 에이비 | 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염 |
| TW202146463A (zh) | 2020-03-05 | 2021-12-16 | 法商賽諾菲公司 | 蛋白酶加工的分子 |
| AU2021236906A1 (en) | 2020-03-18 | 2022-08-18 | Genmab A/S | Antibodies binding to B7H4 |
| CA3181000A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri |
| EP4138925A1 (en) | 2020-04-24 | 2023-03-01 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil |
| WO2021214227A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab |
| EP4138926A1 (en) | 2020-04-24 | 2023-03-01 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox |
| CN111690066B (zh) * | 2020-06-22 | 2022-07-22 | 南京融捷康生物科技有限公司 | 抗IL-4Rα的单域抗体以及应用和药物 |
| US20230340067A1 (en) * | 2020-06-26 | 2023-10-26 | St. Jude Children's Research Hospital, Inc. | Methods of generating an activation inducible expression system in immune cells |
| JP2023534726A (ja) | 2020-07-23 | 2023-08-10 | ジェンマブ ビー．ブイ． | 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用 |
| JP2023539525A (ja) | 2020-09-02 | 2023-09-14 | ジェンマブ エー／エス | 抗体療法 |
| JP2023540732A (ja) | 2020-09-04 | 2023-09-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｃｅａｃａｍ５抗体及びコンジュゲート並びにそれらの使用 |
| WO2022122654A1 (en) * | 2020-12-07 | 2022-06-16 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| KR20240004949A (ko) | 2021-05-07 | 2024-01-11 | 젠맵 에이/에스 | B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물 |
| EP4347640A1 (en) | 2021-05-27 | 2024-04-10 | Sanofi | Fc variant with enhanced affinity to fc receptors and improved thermal stability |
| WO2023275394A1 (en) | 2021-07-02 | 2023-01-05 | Merck Patent Gmbh | Anti-protac antibodies and complexes |
| AU2022330351A1 (en) * | 2021-08-20 | 2024-04-04 | Neovacs | mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF |
| WO2023079057A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
| AU2022425608A1 (en) | 2021-12-30 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| JP2024532455A (ja) * | 2022-03-03 | 2024-09-05 | ファイザー・インク | 多重特異性抗体およびその使用 |
| TW202346354A (zh) | 2022-03-09 | 2023-12-01 | 德商馬克專利公司 | 抗ceacam5抗體及其結合物及用途 |
| EP4245772A1 (en) | 2022-03-18 | 2023-09-20 | Netris Pharma | Anti-netrin-1 antibody to treat liver inflammation |
| EP4249509A1 (en) | 2022-03-22 | 2023-09-27 | Netris Pharma | Anti-netrin-1 antibody against arthritis-associated pain |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| US20240166750A1 (en) | 2022-10-25 | 2024-05-23 | Ablynx N.V. | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION |
| WO2024141496A1 (en) | 2022-12-27 | 2024-07-04 | Merck Patent Gmbh | Vhh anti-protac antibodies and complexes |
| EP4413995A1 (en) | 2023-02-07 | 2024-08-14 | Université de Franche-Comté | Anti-cd123 chimeric antigen receptors t cells for use in the treatement of autoimmune diseases |
| WO2024180085A1 (en) | 2023-02-27 | 2024-09-06 | Netris Pharma | Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains |
| WO2024180192A1 (en) | 2023-03-01 | 2024-09-06 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5 |
| EP4427763A1 (en) | 2023-03-06 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
| EP4434586A1 (en) | 2023-03-23 | 2024-09-25 | Xenothera | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancer and composition thereof |
| WO2024194455A1 (en) | 2023-03-23 | 2024-09-26 | Sanofi | CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY |
Family Cites Families (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) * | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) * | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4716111A (en) * | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| EP0362371A4 (en) | 1988-04-15 | 1990-10-24 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| JP3105898B2 (ja) | 1988-04-16 | 2000-11-06 | セルテック リミテッド | 組換えｄｎａタンパクの製造方法 |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0546073B1 (en) * | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DK0617706T3 (da) | 1991-11-25 | 2001-11-12 | Enzon Inc | Multivalente antigenbindende proteiner |
| ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DE69325777T2 (de) | 1992-06-09 | 2000-03-09 | Hoppe Ag | Riegel und türschloss |
| WO1994004670A1 (en) | 1992-08-26 | 1994-03-03 | President And Fellows Of Harvard College | Use of the cytokine ip-10 as an anti-tumor agent |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| UA40577C2 (ru) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Биспецифическая молекула, которая используется для лизиса опухолевых клеток, способ ее получения, моноклональное антитело (варианты), фармацевтический препарат, фармацевтический набор (варианты), способ удаления опухолевых клеток |
| RU2162711C2 (ru) * | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
| HU222041B1 (hu) | 1993-09-07 | 2003-04-28 | Smithkline Beecham Corporation | Az IL4 által kőzvetített rendellenességek kezelésére használható rekombináns 1L4 antitestek, eljárás ezek előállítására, alkalmazására és az őket tartalmazó gyógyszerkészítmények |
| US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| WO1995009917A1 (en) * | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US5597710A (en) | 1994-03-10 | 1997-01-28 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| CN1173878A (zh) * | 1995-10-16 | 1998-02-18 | 尤尼利弗公司 | 双功能或双价抗体片段类似物 |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| KR100497017B1 (ko) | 1996-03-22 | 2005-11-29 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 고사유도분자ii |
| US6015884A (en) | 1996-03-28 | 2000-01-18 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
| GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| PL193780B1 (pl) | 1997-04-14 | 2007-03-30 | Micromet Ag | Sposób wytwarzania receptora przeciw ludzkim antygenom, ludzkie przeciwciało i środek farmaceutyczny |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2309541C (en) | 1997-11-03 | 2011-01-11 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
| ES2212638T3 (es) * | 1998-09-25 | 2004-07-16 | Lindhofer, Horst, Dr. | Utilizacion de celulas tumorales en tiempo escalonado en combinacion con anticuerpos intactos para la inmunizacion. |
| PL409839A1 (pl) * | 1999-03-25 | 2015-03-30 | Abbott Gmbh & Co.Kg | Ludzkie przeciwciała, które wiążą ludzką IL-12 i sposoby ich wytwarzania |
| AU4761601A (en) | 2000-04-11 | 2001-10-23 | Genentech Inc | Multivalent antibodies and uses therefor |
| CA2405701A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2004511430A (ja) | 2000-05-24 | 2004-04-15 | イムクローン システムズ インコーポレイティド | 二重特異性免疫グロブリン様抗原結合蛋白および製造方法 |
| CN1461344A (zh) * | 2000-07-25 | 2003-12-10 | 免疫医疗公司 | 多价靶结合蛋白 |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| RU2430927C2 (ru) * | 2000-10-20 | 2011-10-10 | Тугаи Сейяку Кабусики Кайся | Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу |
| US20040023337A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
| US20040023338A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-4 mutein proteins, antibodies, compositions, methods and uses |
| JP2005525404A (ja) | 2002-05-01 | 2005-08-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｉｖ感染およびａｉｄｓを処置するためにサイトカインアンタゴニストを使用する方法 |
| US20070104710A1 (en) * | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
| EP1618181B1 (en) | 2003-04-22 | 2014-10-15 | IBC Pharmaceuticals | Polyvalent protein complex |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| EP1692184B1 (en) * | 2003-11-07 | 2012-03-07 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| HRP20231569T1 (hr) | 2003-12-23 | 2024-03-15 | Genentech, Inc. | Nova protutijela protiv il 13 i njihova upotreba |
| US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| KR101184391B1 (ko) | 2004-02-09 | 2013-03-14 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| AU2005217375C1 (en) * | 2004-02-19 | 2012-06-07 | Yale University | Identification of cancer protein biomarkers using proteomic techniques |
| AU2005219837A1 (en) | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 sepecific polypetides and therapeutic uses thereof |
| GB0411186D0 (en) * | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| PT1765397E (pt) * | 2004-05-25 | 2013-02-04 | Tactic Pharma Llc | Anticorpos inibidores que se ligam ao complexo ativador plasminogénico do tipo uroquinasa (upa) e seu receptor (upar) |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| GB0414799D0 (en) * | 2004-07-01 | 2004-08-04 | Glaxo Group Ltd | Immunoglobulins |
| US20060148009A1 (en) | 2004-10-12 | 2006-07-06 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| TW200902555A (en) * | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| GB0514319D0 (en) * | 2005-07-13 | 2006-06-14 | Secr Defence | Antibodies for anthrax |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PL1942939T5 (pl) | 2005-09-30 | 2021-10-11 | Medimmune Limited | Kompozycja przeciwciała interleukiny-13 |
| KR101461263B1 (ko) * | 2005-10-21 | 2014-11-17 | 노파르티스 아게 | Ｉｌ-13에 대항한 인간 항체 및 치료적 용도 |
| GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| CA2636854A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind il-4 and/or il-13 |
| AU2007228943B2 (en) | 2006-03-22 | 2012-03-22 | Apogenix Gmbh | Antibody specific for human IL-4 for the treament of cancer |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| TWI719112B (zh) * | 2011-03-16 | 2021-02-21 | 賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| TWI745962B (zh) * | 2014-06-27 | 2021-11-11 | 法商賽諾菲公司 | 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法 |
-
2007
- 2007-10-15 EP EP07291259A patent/EP2050764A1/en not_active Ceased
-
2008
- 2008-10-13 PE PE2008001760A patent/PE20091382A1/es active IP Right Grant
- 2008-10-14 LT LTEP12006797.0T patent/LT2573119T/lt unknown
- 2008-10-14 TR TR2018/02225T patent/TR201802225T4/tr unknown
- 2008-10-14 DK DK12006790.5T patent/DK2573121T3/en active
- 2008-10-14 EP EP12006791.3A patent/EP2574630B1/en active Active
- 2008-10-14 SI SI200831938T patent/SI2573119T1/en unknown
- 2008-10-14 TR TR2018/10005T patent/TR201810005T4/tr unknown
- 2008-10-14 LT LTEP12006791.3T patent/LT2574630T/lt unknown
- 2008-10-14 DK DK12006789.7T patent/DK2574629T3/en active
- 2008-10-14 PT PT120067905T patent/PT2573121T/pt unknown
- 2008-10-14 EP EP12006796A patent/EP2573118A1/en not_active Withdrawn
- 2008-10-14 EP EP12006797.0A patent/EP2573119B1/en active Active
- 2008-10-14 UA UAA201005855A patent/UA104130C2/ru unknown
- 2008-10-14 EP EP12006793A patent/EP2574626A1/en not_active Withdrawn
- 2008-10-14 RS RS20180809A patent/RS57396B1/sr unknown
- 2008-10-14 HU HUE12006791A patent/HUE038444T2/hu unknown
- 2008-10-14 KR KR1020107008006A patent/KR101681909B1/ko active IP Right Grant
- 2008-10-14 NZ NZ584658A patent/NZ584658A/xx unknown
- 2008-10-14 RU RU2013120318/10A patent/RU2580049C2/ru active
- 2008-10-14 ES ES12006790.5T patent/ES2647872T3/es active Active
- 2008-10-14 HU HUE12006789A patent/HUE036530T2/hu unknown
- 2008-10-14 KR KR1020197005667A patent/KR20190022928A/ko not_active Application Discontinuation
- 2008-10-14 PL PL12006790T patent/PL2573121T3/pl unknown
- 2008-10-14 CL CL2008003037A patent/CL2008003037A1/es unknown
- 2008-10-14 RS RS20180201A patent/RS56914B1/sr unknown
- 2008-10-14 SG SG2012076568A patent/SG185303A1/en unknown
- 2008-10-14 EP EP12006794A patent/EP2573116A1/en not_active Ceased
- 2008-10-14 PL PL08839958T patent/PL2205640T3/pl unknown
- 2008-10-14 SG SG10201602770UA patent/SG10201602770UA/en unknown
- 2008-10-14 DK DK08839958.9T patent/DK2205640T3/en active
- 2008-10-14 EP EP12006792A patent/EP2573115A1/en not_active Ceased
- 2008-10-14 KR KR1020167033258A patent/KR101823859B1/ko active IP Right Grant
- 2008-10-14 HU HUE12006790A patent/HUE037205T2/hu unknown
- 2008-10-14 EP EP12006790.5A patent/EP2573121B1/en active Active
- 2008-10-14 CN CN200880111668.6A patent/CN101827863B/zh active Active
- 2008-10-14 EP EP12006789.7A patent/EP2574629B1/en active Active
- 2008-10-14 EP EP12006795A patent/EP2573117A1/en not_active Withdrawn
- 2008-10-14 NZ NZ601342A patent/NZ601342A/en unknown
- 2008-10-14 DK DK12006791.3T patent/DK2574630T3/en active
- 2008-10-14 MY MYPI2010001251A patent/MY171214A/en unknown
- 2008-10-14 RS RS20180381A patent/RS57060B1/sr unknown
- 2008-10-14 MX MX2012010171A patent/MX363634B/es unknown
- 2008-10-14 BR BRPI0818677A patent/BRPI0818677B8/pt active IP Right Grant
- 2008-10-14 LT LTEP12006790.5T patent/LT2573121T/lt unknown
- 2008-10-14 NO NO12006789A patent/NO2574629T3/no unknown
- 2008-10-14 US US12/682,864 patent/US8388965B2/en active Active
- 2008-10-14 PT PT120067897T patent/PT2574629T/pt unknown
- 2008-10-14 CN CN201710131539.4A patent/CN106986938B/zh active Active
- 2008-10-14 MX MX2012010172A patent/MX363901B/es unknown
- 2008-10-14 SG SG10201913838RA patent/SG10201913838RA/en unknown
- 2008-10-14 RS RS20140077A patent/RS53175B/en unknown
- 2008-10-14 DK DK12006797.0T patent/DK2573119T3/en active
- 2008-10-14 MX MX2012002055A patent/MX363638B/es unknown
- 2008-10-14 AU AU2008312655A patent/AU2008312655B2/en active Active
- 2008-10-14 ES ES12006789.7T patent/ES2660152T3/es active Active
- 2008-10-14 CA CA2702473A patent/CA2702473C/en active Active
- 2008-10-14 UA UAA201310544A patent/UA118949C2/uk unknown
- 2008-10-14 MX MX2012002053A patent/MX354150B/es unknown
- 2008-10-14 KR KR1020187002319A patent/KR101954596B1/ko active IP Right Grant
- 2008-10-14 SI SI200831976T patent/SI2574630T1/en unknown
- 2008-10-14 PT PT88399589T patent/PT2205640E/pt unknown
- 2008-10-14 CA CA3071750A patent/CA3071750C/en active Active
- 2008-10-14 RS RS20171174A patent/RS56553B1/sr unknown
- 2008-10-14 PL PL12006791T patent/PL2574630T3/pl unknown
- 2008-10-14 RU RU2010119521/10A patent/RU2488595C2/ru active
- 2008-10-14 ES ES12006791.3T patent/ES2679281T3/es active Active
- 2008-10-14 WO PCT/US2008/079787 patent/WO2009052081A2/en active Application Filing
- 2008-10-14 SI SI200831924T patent/SI2574629T1/en unknown
- 2008-10-14 NZ NZ709353A patent/NZ709353A/en unknown
- 2008-10-14 CN CN202110668094.XA patent/CN113480647A/zh active Pending
- 2008-10-14 PT PT120067970T patent/PT2573119T/pt unknown
- 2008-10-14 ES ES08839958.9T patent/ES2447915T3/es active Active
- 2008-10-14 EP EP08839958.9A patent/EP2205640B1/en active Active
- 2008-10-14 LT LTEP12006789.7T patent/LT2574629T/lt unknown
- 2008-10-14 EP EP19214415.2A patent/EP3686220A1/en active Pending
- 2008-10-14 PL PL12006789T patent/PL2574629T3/pl unknown
- 2008-10-14 CA CA3015470A patent/CA3015470C/en active Active
- 2008-10-14 PL PL12006797T patent/PL2573119T3/pl unknown
- 2008-10-14 SG SG10201913836SA patent/SG10201913836SA/en unknown
- 2008-10-14 AR ARP080104471A patent/AR068861A1/es active IP Right Grant
- 2008-10-14 PT PT120067913T patent/PT2574630T/pt unknown
- 2008-10-14 SI SI200831156T patent/SI2205640T1/sl unknown
- 2008-10-14 NO NO12006790A patent/NO2573121T3/no unknown
- 2008-10-14 SI SI200831890T patent/SI2573121T1/en unknown
- 2008-10-14 MX MX2010003290A patent/MX2010003290A/es active IP Right Grant
- 2008-10-14 ES ES12006797.0T patent/ES2664476T3/es active Active
- 2008-10-14 KR KR1020147024155A patent/KR101682373B1/ko active IP Right Grant
- 2008-10-14 HU HUE12006797A patent/HUE038556T2/hu unknown
- 2008-10-14 JP JP2010530058A patent/JP5858616B2/ja active Active
- 2008-10-15 TW TW104112966A patent/TWI616205B/zh active
- 2008-10-15 TW TW097139453A patent/TWI619508B/zh active
- 2008-10-15 TW TW106136056A patent/TW201825117A/zh unknown
- 2008-10-15 TW TW104112967A patent/TWI616206B/zh active
- 2008-10-15 PA PA20088799001A patent/PA8799001A1/es unknown
- 2008-10-15 UY UY31394A patent/UY31394A1/es not_active Application Discontinuation
-
2010
- 2010-03-22 TN TNP2010000126A patent/TN2010000126A1/fr unknown
- 2010-03-23 NI NI2010000406A patent/NI201000406A/es unknown
- 2010-03-23 NI NI2010000402A patent/NI201000402A/es unknown
- 2010-03-23 NI NI2010000401A patent/NI201000401A/es unknown
- 2010-03-23 NI NI2010000404A patent/NI201000404A/es unknown
- 2010-03-23 NI NI2010000403A patent/NI201000403A/es unknown
- 2010-03-23 NI NI201000040A patent/NI201000040A/es unknown
- 2010-03-23 NI NI2010000405A patent/NI201000405A/es unknown
- 2010-03-24 GT GT201000067A patent/GT201000067A/es unknown
- 2010-03-24 ZA ZA2010/02069A patent/ZA201002069B/en unknown
- 2010-03-25 MX MX2012002056A patent/MX354666B/es unknown
- 2010-03-25 CR CR11337A patent/CR11337A/es unknown
- 2010-04-11 IL IL205005A patent/IL205005A/en active IP Right Grant
- 2010-04-14 DO DO2010000109A patent/DOP2010000109A/es unknown
- 2010-04-14 HN HN2010000710A patent/HN2010000710A/es unknown
- 2010-05-10 MA MA32823A patent/MA31838B1/fr unknown
-
2012
- 2012-11-15 CL CL2012003196A patent/CL2012003196A1/es unknown
-
2013
- 2013-02-04 US US13/758,858 patent/US20130209469A1/en not_active Abandoned
- 2013-03-11 US US13/794,310 patent/US20130251717A1/en not_active Abandoned
- 2013-03-11 US US13/794,354 patent/US20130236462A1/en not_active Abandoned
- 2013-03-11 US US13/794,341 patent/US20130236461A1/en not_active Abandoned
- 2013-03-11 US US13/794,320 patent/US20130236460A1/en not_active Abandoned
- 2013-03-11 US US13/794,370 patent/US20130236463A1/en not_active Abandoned
- 2013-03-11 US US13/794,384 patent/US20130251718A1/en not_active Abandoned
- 2013-03-11 US US13/794,394 patent/US20130259866A1/en not_active Abandoned
- 2013-03-11 US US13/794,295 patent/US9738728B2/en active Active
- 2013-03-15 US US13/831,884 patent/US20130243778A1/en not_active Abandoned
- 2013-03-15 US US13/831,856 patent/US20130243776A1/en not_active Abandoned
- 2013-03-15 US US13/831,866 patent/US20140023649A1/en not_active Abandoned
- 2013-03-15 US US13/831,862 patent/US9732162B2/en active Active
- 2013-04-04 AU AU2013202389A patent/AU2013202389B9/en active Active
- 2013-04-10 AU AU2013203339A patent/AU2013203339B9/en active Active
- 2013-04-10 AU AU2013203328A patent/AU2013203328B9/en active Active
- 2013-04-10 AU AU2013203324A patent/AU2013203324C1/en active Active
- 2013-05-21 PH PH12013501033A patent/PH12013501033A1/en unknown
- 2013-05-21 PH PH12013501032A patent/PH12013501032A1/en unknown
- 2013-07-12 CL CL2013002040A patent/CL2013002040A1/es unknown
- 2013-07-12 CL CL2013002039A patent/CL2013002039A1/es unknown
- 2013-12-12 DO DO2013000302A patent/DOP2013000302A/es unknown
- 2013-12-12 DO DO2013000301A patent/DOP2013000301A/es unknown
-
2014
- 2014-02-18 HR HRP20140150AT patent/HRP20140150T1/hr unknown
- 2014-02-20 CY CY20141100136T patent/CY1114987T1/el unknown
-
2015
- 2015-02-26 CR CR20150102A patent/CR20150102A/es unknown
- 2015-02-26 CR CR20150101A patent/CR20150101A/es unknown
- 2015-02-26 CR CR20150103A patent/CR20150103A/es unknown
- 2015-07-31 JP JP2015151693A patent/JP6280526B2/ja active Active
- 2015-07-31 JP JP2015151694A patent/JP6126652B2/ja active Active
- 2015-07-31 JP JP2015151695A patent/JP6126653B2/ja active Active
- 2015-09-29 RU RU2015141428A patent/RU2705551C2/ru active
- 2015-09-29 RU RU2015141418A patent/RU2721236C2/ru active
- 2015-12-10 CR CR20150654A patent/CR20150654A/es unknown
-
2016
- 2016-11-29 IL IL249289A patent/IL249289A0/en unknown
-
2017
- 2017-07-10 US US15/645,765 patent/US10759871B2/en active Active
- 2017-11-16 HR HRP20171765TT patent/HRP20171765T1/hr unknown
- 2017-11-22 CY CY20171101220T patent/CY1119875T1/el unknown
-
2018
- 2018-01-18 JP JP2018006055A patent/JP2018078907A/ja active Pending
- 2018-02-21 HR HRP20180320TT patent/HRP20180320T1/hr unknown
- 2018-02-22 CY CY20181100211T patent/CY1120033T1/el unknown
- 2018-03-27 HR HRP20180517TT patent/HRP20180517T1/hr unknown
- 2018-03-30 CY CY20181100360T patent/CY1120108T1/el unknown
- 2018-07-10 HR HRP20181085TT patent/HRP20181085T1/hr unknown
- 2018-07-17 CY CY181100741T patent/CY1120887T1/el unknown
- 2018-10-18 AR ARP180103042A patent/AR122833A2/es unknown
- 2018-10-18 AR ARP180103043A patent/AR122834A2/es unknown
-
2020
- 2020-07-28 US US16/941,272 patent/US11453727B2/en active Active
-
2022
- 2022-08-10 US US17/818,927 patent/US20230235088A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015141428A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| JP7019198B2 (ja) | 補体関連疾患の予防及び治療のためのｃ５抗体及び方法 | |
| US20210171611A1 (en) | Antibody that binds to envelope glycoprotein of sever fever with thrombocytopenia syndrome virus and use for same | |
| EP2500361B1 (en) | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof | |
| JP2022061992A5 (ru) | ||
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| AU2016223095B2 (en) | Antibodies to tau and uses thereof | |
| TW201031421A (en) | IL-1 binding proteins | |
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| JP2012525829A5 (ru) | ||
| JP2020513791A5 (ru) | ||
| TW201138825A (en) | TNF-α binding proteins | |
| JP2012501670A5 (ru) | ||
| KR20120135419A (ko) | 치료학적 ｄｌｌ４ 결합 단백질 | |
| JP2011207882A5 (ru) | ||
| JP2015511817A (ja) | Ｃｄｉｍ結合タンパク質及びその使用 | |
| JP2021512159A5 (ru) | ||
| TW201134489A (en) | Basigin binding proteins | |
| KR20100074181A (ko) | β-아밀로이드 펩티드에 대한 인간화 항체 | |
| JP2015518368A5 (ru) | ||
| KR20220030934A (ko) | 항-gal9 면역-억제 결합 분자 | |
| CA3143957A1 (en) | Anti-pd-l1 antibodies | |
| JPWO2019204462A5 (ru) | ||
| JPWO2022111425A5 (ru) |